Haemostatic challenges in the cancer patient: Focus on the perioperative period

Best Practice and Research: Clinical Anaesthesiology

Volumn 27, Issue 4, 2013, Pages 493-511

  Burbury, Kate ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

cancer; haemorrhage; hypercoagulability; perioperative; thrombo embolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CANCER PROCOAGULANT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DABIGATRAN; DIPYRIDAMOLE; FIBRINOGEN; FONDAPARINUX; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; RIVAROXABAN; SEMULOPARIN; TICAGRELOR; TICLOPIDINE; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CANCER PATIENT; CANCER SURGERY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; EMBOLISM PREVENTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; MOBILIZATION; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PATIENT ASSESSMENT; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK ASSESSMENT; SURGICAL RISK; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TIME TO TREATMENT; TREATMENT DURATION;

CANCER; HAEMORRHAGE; HYPERCOAGULABILITY; PERIOPERATIVE; THROMBO-EMBOLISM;

ANTICOAGULANTS; DECISION MAKING; HEMORRHAGE; HEMOSTASIS; HUMANS; NEOPLASMS; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD; RISK; THROMBOEMBOLISM; TIME FACTORS;

EID: 84888431301     PISSN: 15216896     EISSN: 1532169X     Source Type: Journal    
DOI: 10.1016/j.bpa.2013.09.001     Document Type: Review

References (104)

1. A. Falanga, L. Russo, and C. Verzeroli Mechanisms of thrombosis in cancer Thromb Res 131 Suppl. 1 2013 S59 S62
2. G.H. Guyatt, J.W. Eikelboom, and M.K. Gould Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e185S e194S
3. G.H. Lyman, and N.M. Kuderer Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines Thromb Res 125 Suppl. 2 2010 S120 S127
4. S. Siragusa, U. Armani, and M. Carpenedo Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1) Thromb Res 129 5 2012 e171 e176
5. M. Mandala, A. Falanga, and F. Roila Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Ann Oncol 22 Suppl. 6 2011 vi85 vi92
6. NHMRC Stop the clot: integrating VTE prevention guideline recommendations into routine hospital care 3rd ed. 2011 National Health and Medical Research Council
7. NCCN Guidelines version 2. 2011 venous thromboembolic disease 2011 NCCN Guidelines
8. B.D. Sites, V.W. Chan, and J.M. Neal The American Society of Regional Anesthesia and Pain Medicine and the European Society of Regional Anaesthesia and Pain Therapy joint committee recommendations for education and training in ultrasound-guided regional anesthesia Reg Anesth Pain Med 35 2 Suppl. 2010 S74 S80
9. M.K. Gould, D.A. Garcia, and S.M. Wren Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e227S e277S
10. C. Kearon, E.A. Akl, and A.J. Comerota Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e419S e494S
11. G.H. Lyman, A.A. Khorana, and N.M. Kuderer Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 31 17 2013 2189 2204
12. A. Falanga, M. Marchetti, and A. Vignoli Coagulation and cancer: biological and clinical aspects J Thromb Haemost JTH 11 2 2013 223 233 [Epub 2013/01/03]
13. M. Anand, and D.J. Brat Oncogenic regulation of tissue factor and thrombosis in cancer Thromb Res 129 Suppl. 1 2012 S46 S49
14. J.E. Geddings, and N. Mackman Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients Blood 122 11 2013 Sep 12 1873 1880
15. C. Hernandez, J. Orbe, and C. Roncal Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients Thromb Haemost 110 3 2013 598 608
16. A.A. Khorana Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb Res 129 Suppl. 1 2012 S10 S15
17. G. Agnelli, M. Verso, and W. Ageno The MASTER registry on venous thromboembolism: description of the study cohort Thromb Res 121 5 2008 605 610
18. A.A. Khorana, C.W. Francis, and E. Culakova Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients Cancer 110 10 2007 2339 2346
19. H.M. Otten, M.H. Prins, and S.M. Smorenburg Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor Haemostasis 30 Suppl. 2 2000 72 76 [discussion 63]
20. H.K. Chew, T. Wun, and D. Harvey Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 4 2006 458 464
21. A. Alcalay, T. Wun, and V. Khatri Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival J Clin Oncol 24 7 2006 1112 1118
22. N.M. Kuderer, T.L. Ortel, and C.W. Francis Impact of venous thromboembolism and anticoagulation on cancer and cancer survival J Clin Oncol 27 29 2009 4902 4911
23. D. Imberti, G. Agnelli, and W. Ageno Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry Haematologica 93 2 2008 273 278
24. P. Prandoni, A.W. Lensing, and A. Piccioli Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 10 2002 3484 3488
25. A.Y. Lee Anticoagulation in the treatment of established venous thromboembolism in patients with cancer J Clin Oncol 27 29 2009 4895 4901
26. W. Ruf, and B.M. Mueller Thrombin generation and the pathogenesis of cancer Semin Thromb Hemost 32 Suppl. 1 2006 61 68
27. F.R. Rickles, S. Patierno, and P.M. Fernandez Tissue factor, thrombin, and cancer Chest 124 3 Suppl. 2003 58S 68S
28. C.E. Mahan, M.T. Holdsworth, and S.M. Welch Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event Thromb Haemost 106 3 2011 405 415
29. A.K. Kakkar Current use of venous thromboembolism prophylaxis in cancer patients Clin Adv Hematol Oncol 7 4 2009 231 233
30. A.T. Cohen, V.F. Tapson, and J.F. Bergmann Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study Lancet 371 9610 2008 387 394
31. C. Kalka, D. Spirk, and K.A. Siebenrock Lack of extended venous thromboembolism prophylaxis in high-risk patients undergoing major orthopaedic or major cancer surgery. Electronic Assessment of VTE Prophylaxis in High-Risk Surgical Patients at Discharge from Swiss Hospitals (ESSENTIAL) Thromb Haemost 102 1 2009 56 61
32. I. Pabinger, and C. Ay Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis? Hamostaseologie 31 4 2011
33. A.A. Khorana, N.M. Kuderer, and E. Culakova Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 10 2008 4902 4907
34. R.P. Merkow, K.Y. Bilimoria, and M.D. McCarter Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis Ann Surg 254 1 2011 131 137
35. G. Agnelli, G. Bolis, and L. Capussotti A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project Ann Surg 243 1 2006 89 95
36. D. Bergqvist, G. Agnelli, and A.T. Cohen Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N Engl J Med 346 13 2002 975 980
37. E.A. Akl, I. Terrenato, and M. Barba Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis Arch Intern Med 168 12 2008 1261 1269
38. A.T. Cohen, H.M. Zaw, and R. Alikhan Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: the MEDENOX trial Semin Hematol 38 2 Suppl. 5 2001 31 38
39. A.T. Cohen, B.L. Davidson, and A.S. Gallus Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial BMJ 332 7537 2006 325 329
40. P. Mismetti, S. Laporte, and J.Y. Darmon Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery Br J Surg 88 7 2001 913 930
41. C.T. Bradley, K.J. Brasel, and J.J. Miller Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery Ann Surg Oncol 17 1 2010 31 39
42. V.V. Kakkar Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis Thromb Res 81 2 Suppl. 1996 S75 S77
43. G.H. Guyatt, S.L. Norris, and S. Schulman Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 53S 70S
44. G. Oster, R.L. Tuden, and G.A. Colditz Prevention of venous thromboembolism after general surgery. Cost-effectiveness analysis of alternative approaches to prophylaxis Am J Med 82 5 1987 889 899
45. A. Heerey, and S. Suri Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery Pharmacoeconomics 23 9 2005 927 944
46. T.D. Szucs, and W. Schramm The cost-effectiveness of low-molecular-weight heparin vs unfractionated heparin in general and orthopaedic surgery: an analysis for the German healthcare system Pharmacol Res 40 1 1999 83 89
47. E. Etchells, R.S. McLeod, and W. Geerts Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery Arch Intern Med 159 11 1999 1221 1228
48. G.L. Maxwell, E.R. Myers, and D.L. Clarke-Pearson Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery Obstet Gynecol 95 2 2000 206 214
49. L. Dainty, G.L. Maxwell, and D.L. Clarke-Pearson Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery Gynecol Oncol 93 2 2004 366 373
50. R. Farias-Eisner, R. Horblyuk, and M. Franklin Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery Curr Med Res Opin 25 5 2009 1081 1087
51. G.H. Guyatt, E.A. Akl, and M. Crowther Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 7S 47S
52. T. Treasure, and J. Hill NICE guidance on reducing the risk of venous thromboembolism in patients admitted to hospital J R Soc Med 103 6 2010 210 212 [Epub 2010/06/02]
53. K.M. Brose, and A.Y. Lee Cancer-associated thrombosis: prevention and treatment Curr Oncol 15 Suppl. 1 2008 S58 S67
54. P.M. Erkens, and M.H. Prins Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism Cochrane Database Syst Rev 9 2010 CD001100
55. T.E. Warkentin, and A. Greinacher So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? Chest 132 4 2007 1108 1110
56. G. Agnelli, D. Bergqvist, and A.T. Cohen Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery Br J Surg 92 10 2005 1212 1220
57. A.A. Kakkar, G. Fisher, and W. George The ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism in patients undergoing major abdominal surgery Blood 2011 ASH2011 (Abstract 188)
58. G. Agnelli, D.J. George, and A.K. Kakkar Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer N Engl J Med 366 7 2012 601 609
59. V. Sehgal, S.J. Bajwa, and A. Bajaj New orally active anticoagulants in critical care and anesthesia practice: the good, the bad and the ugly Ann Card Anaesth 16 3 2013 193 200
60. S. Schulman, and M.A. Crowther How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 13 2012 3016 3023
61. A.C. Spyropoulos, and J.D. Douketis How I treat anticoagulated patients undergoing an elective procedure or surgery Blood 120 15 2012 2954 2962 [Epub 2012/08/31]
62. R.W. Eppsteiner, J.J. Shin, and J. Johnson Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis World J Surg 34 1 2010 10 19
63. A.G. Turpie, K.A. Bauer, and J.A. Caprini Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison JTH 5 9 2007 1854 1861
64. A. Rasmussen, P.T. Hansen, and J. Lindholt Venous thrombosis after abdominal surgery. A comparison between subcutaneous heparin and antithrombotic stockings, or both J Med 19 3-4 1988 193 201
65. D. Bergqvist, and B. Lindblad The thromboprophylactic effect of graded elastic compression stockings in combination with dextran 70 Arch Surg 119 11 1984 1329 1331
66. P. Wille-Jorgensen, J. Kjaergaard, and T. Jorgensen Postoperative thromboembolic complications despite heparin prophylaxis in major abdominal surgery Ann Chir Gynaecol 74 3 1985 130 133
67. P. Wille-Jorgensen, O. Hauch, and B. Dimo Prophylaxis of deep venous thrombosis after acute abdominal operation Surg Gynecol Obstet 172 1 1991 44 48
68. P. Wille-Jorgensen Prophylaxis of postoperative thromboembolism with combined methods Semin Thromb Hemost 17 Suppl. 3 1991 272 279
69. R. Eisele, L. Kinzl, and T. Koelsch Rapid-inflation intermittent pneumatic compression for prevention of deep venous thrombosis J Bone Joint Surg Am 89 5 2007 1050 1056
70. R.C. Smith, R.A. Elton, and J.D. Orr Dextran and intermittent pneumatic compression in prevention of postoperative deep vein thrombosis: multiunit trial Br Med J 1 6118 1978 952 954
71. Y. Silbersack, B.M. Taute, and W. Hein Prevention of deep-vein thrombosis after total hip and knee replacement. Low-molecular-weight heparin in combination with intermittent pneumatic compression J Bone Joint Surg Br 86 6 2004 809 812 [Epub 2004/08/28]
72. H. Decousus, A. Leizorovicz, and F. Parent A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group N Engl J Med 338 7 1998 409 415
73. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study Circulation 112 3 2005 416 422
74. N.J. Birkmeyer, D. Share, and O. Baser Preoperative placement of inferior vena cava filters and outcomes after gastric bypass surgery Ann Surg 252 2 2010 313 318
75. A. Rajasekhar, R. Lottenberg, and L. Lottenberg Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systematic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines J Thromb Thrombolysis 32 1 2011 40 46
76. T.D. Girard, J.T. Philbrick, and J. Fritz Angle Prophylactic vena cava filters for trauma patients: a systematic review of the literature Thromb Res 112 5-6 2003 261 267
77. A.K. Kakkar, B. Brenner, and O.E. Dahl Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 9632 2008 31 39
78. B.I. Eriksson, L.C. Borris, and R.J. Friedman Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 26 2008 2765 2775
79. M.R. Lassen, W. Ageno, and L.C. Borris Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 26 2008 2776 2786
80. M.R. Lassen, A. Gallus, and G.E. Raskob Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 26 2010 2487 2498
81. M.R. Lassen, G.E. Raskob, and A. Gallus Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 9717 2010 807 815
82. M.V. Huisman, D.J. Quinlan, and O.E. Dahl Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials Circ Cardiovasc Qual Outcomes 3 6 2010 652 660
83. A.V. Bendetowicz, S. Beguin, and H. Caplain Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin - a three way cross over study in human volunteers Thromb Haemost 71 3 1994 305 313
84. G.E. Raskob, and J. Hirsh Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery Chest 124 6 Suppl. 2003 379S 385S
85. C. Papakostidis, P.J. Harwood, and E.J. Karadimas The timing of drug administration for thromboprophylaxis following orthopaedic surgery: evidence and controversies related to treatment initiation and duration Curr Vasc Pharmacol 9 1 2011 11 18
86. D. Warwick, and N. Rosencher The 'critical thrombosis period' in major orthopedic surgery: when to start and when to stop prophylaxis Clin Appl Thrombosis/Hemostasis Off J Int Acad Clin Appl Thrombosis/Hemostasis 16 4 2010 394 405
87. D. Bergqvist Prolonged postoperative thromboprophylaxis - current state of knowledge Lakartidningen 99 13 2002 1461 1463
88. J. Hammond, C. Kozma, and J.C. Hart Rates of venous thromboembolism among patients with major surgery for cancer Ann Surg Oncol 18 12 2011 3240 3247
89. A. Peedicayil, A. Weaver, and X. Li Incidence and timing of venous thromboembolism after surgery for gynecological cancer Gynecol Oncol 121 1 2011 64 69
90. E.A. Akl, I. Terrenato, and M. Barba Extended perioperative thromboprophylaxis in patients with cancer. A systematic review Thromb Haemost 100 6 2008 1176 1180
91. V.V. Kakkar, J.L. Balibrea, and J. Martinez-Gonzalez Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study JTH 8 6 2010 1223 1229
92. M.S. Rasmussen, L.N. Jorgensen, and P. Wille-Jorgensen Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery Cochrane Database Syst Rev 1 2009 CD004318
93. F.J. Bottaro, M.C. Elizondo, and C. Doti Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis Thromb Haemost 99 6 2008 1104 1111
94. W.H. Geerts, D. Bergqvist, and G.F. Pineo Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 6 Suppl. 2008 381S 453S
95. M.H. Huo, and A.C. Spyropoulos The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies J Thromb Thrombolysis 31 2 2011 196 208
96. P. Smart, K. Burbury, and S. Lingaratnam Thromboprophylaxis among Australasian colorectal surgeons ANZ J Surg 83 9 2013 646 650
97. M.A. Allman-Farinelli, T. Chey, and A.E. Bauman Age, period and birth cohort effects on prevalence of overweight and obesity in Australian adults from 1990 to 2000 Eur J Clin Nutr 62 7 2008 898 907
98. M.A. Allman-Farinelli Obesity and venous thrombosis: a review Semin Thromb Hemost 37 8 2011 903 907
99. M.M. Samama An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study Arch Intern Med 160 22 2000 3415 3420
100. G.T. Gerotziafas, A.D. Petropoulou, and E. Verdy Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation JTH 5 5 2007 955 962
101. M.H. Eckman, J.K. Erban, and S.K. Singh Screening for the risk for bleeding or thrombosis Ann Intern Med 138 3 2003 W15 W24
102. W.H. Dzik Predicting hemorrhage using preoperative coagulation screening assays Curr Hematol Rep 3 5 2004 324 330
103. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies Anesthesiology 105 1 2006 198 208
104. M. Greaves, and H.G. Watson Approach to the diagnosis and management of mild bleeding disorders JTH 5 Suppl. 1 2007 167 174